PURPOSE: A retrospective study of radiation-induced apoptosis in CD4 and CD8 T-lymphocytes, from 12 cancer patients who displayed enhanced toxicity to radiation therapy and 9 ataxia telangiectasia patients, was performed to test for altered response compared to healthy blood-donors and normal cancer patients. METHODS AND MATERIALS: Three milliliters of heparinized blood from each donor was sent via express post to the Paul Scherrer Institute (PSI) for subsequent examination. The blood was diluted 1:10 in RPMI medium, irradiated with 0-, 2-, or 9-Gy X-rays, and incubated for 48 h. CD4 and CD8 T-lymphocytes were then labeled using FITC-conjugated antibodies, erythrocytes were lysed, and the DNA stained with propidium iodide. Subsequently, cells were analyzed using a Becton Dickinson FACScan flow cytometer. Radiation-induced apoptosis was recognized in leukocytes as reduced DNA content attributed to apoptosis-associated changes in chromatin structure. Apoptosis was confirmed by light microscopy, electron microscopy, and by the use of commercially available apoptosis detection kits (in situ nick translation and Annexin V). Data from hypersensitive individuals were compared to a standard database of 105 healthy blood-donors, and a database of 48 cancer patient blood donors who displayed normal toxicity to radiation therapy. To integrate radiosensitivity results from CD4 and CD8 T-lymphocytes after 2 and 9 Gy, z-score analyses were performed. RESULTS: A cohort of 12 hypersensitive patients was evaluated; 8 showed enhanced early toxicity, 3 showed enhanced late toxicity, and 1 showed both. The cohort displayed less radiation-induced apoptosis (-1.8 sigma) than average age-matched donors. A cohort of 9 ataxia telangiectasia homozygotes displayed even less apoptosis (-3.6 sigma). CONCLUSION: The leukocyte apoptosis assay appears to be a useful predictor of individuals likely to display increased toxicity to radiation therapy; however, validation of this requires a prospective study.
PURPOSE: A retrospective study of radiation-induced apoptosis in CD4 and CD8 T-lymphocytes, from 12 cancerpatients who displayed enhanced toxicity to radiation therapy and 9 ataxia telangiectasiapatients, was performed to test for altered response compared to healthy blood-donors and normal cancerpatients. METHODS AND MATERIALS: Three milliliters of heparinized blood from each donor was sent via express post to the Paul Scherrer Institute (PSI) for subsequent examination. The blood was diluted 1:10 in RPMI medium, irradiated with 0-, 2-, or 9-Gy X-rays, and incubated for 48 h. CD4 and CD8 T-lymphocytes were then labeled using FITC-conjugated antibodies, erythrocytes were lysed, and the DNA stained with propidium iodide. Subsequently, cells were analyzed using a Becton Dickinson FACScan flow cytometer. Radiation-induced apoptosis was recognized in leukocytes as reduced DNA content attributed to apoptosis-associated changes in chromatin structure. Apoptosis was confirmed by light microscopy, electron microscopy, and by the use of commercially available apoptosis detection kits (in situ nick translation and Annexin V). Data from hypersensitive individuals were compared to a standard database of 105 healthy blood-donors, and a database of 48 cancerpatient blood donors who displayed normal toxicity to radiation therapy. To integrate radiosensitivity results from CD4 and CD8 T-lymphocytes after 2 and 9 Gy, z-score analyses were performed. RESULTS: A cohort of 12 hypersensitivepatients was evaluated; 8 showed enhanced early toxicity, 3 showed enhanced late toxicity, and 1 showed both. The cohort displayed less radiation-induced apoptosis (-1.8 sigma) than average age-matched donors. A cohort of 9 ataxia telangiectasia homozygotes displayed even less apoptosis (-3.6 sigma). CONCLUSION: The leukocyte apoptosis assay appears to be a useful predictor of individuals likely to display increased toxicity to radiation therapy; however, validation of this requires a prospective study.
Authors: David Azria; Mahmut Ozsahin; Andrew Kramar; Sheila Peters; David P Atencio; Nigel E A Crompton; Françoise Mornex; André Pèlegrin; Jean-Bernard Dubois; René-Olivier Mirimanoff; Barry S Rosenstein Journal: Clin Cancer Res Date: 2008-10-01 Impact factor: 12.531
Authors: Beatriz Pinar; Luis Alberto Henríquez-Hernández; Pedro C Lara; Elisa Bordon; Carlos Rodriguez-Gallego; Marta Lloret; Maria Isabel Nuñez; Mariano Ruiz De Almodovar Journal: Radiat Oncol Date: 2010-09-24 Impact factor: 3.481
Authors: Kerri E Rieger; Wan-Jen Hong; Virginia Goss Tusher; Jean Tang; Robert Tibshirani; Gilbert Chu Journal: Proc Natl Acad Sci U S A Date: 2004-04-19 Impact factor: 11.205
Authors: Carsten Herskind; Christopher J Talbot; Sarah L Kerns; Marlon R Veldwijk; Barry S Rosenstein; Catharine M L West Journal: Cancer Lett Date: 2016-03-02 Impact factor: 8.679
Authors: Elisa Bordón; Luis Alberto Henríquez Hernández; Pedro C Lara; Beatriz Pinar; Fausto Fontes; Carlos Rodríguez Gallego; Marta Lloret Journal: Radiat Oncol Date: 2009-11-26 Impact factor: 3.481
Authors: Elisa Bordón; Luis Alberto Henríquez-Hernández; Pedro C Lara; Ana Ruíz; Beatriz Pinar; Carlos Rodríguez-Gallego; Marta Lloret Journal: Radiat Oncol Date: 2010-01-28 Impact factor: 3.481